Genmab acquieres worldwide rights for HUMAX-CD4

05-Jul-2005

Genmab A/S announced that it has licensed from Medarex, Inc. the European and Asian rights to utilize Medarex's UltiMAb® technology to develop and commercialize antibodies raised against the CD4 antigen, including HuMax-CD4(TM), a fully human antibody that Genmab currently has in Phase III clinical studies to treat cutaneous T-cell lymphoma. With the acquisition of this new territory, Genmab now holds worldwide rights to HuMax®-CD4.

Under the terms of the agreement, Genmab has agreed to pay Medarex an upfront payment of USD 2 million, and Medarex is entitled to potential total milestone and license fee payments of USD 12.5 million, as well as royalties that could reach double digits for a successfully commercialized product in the new territories.

"We believe that consolidating the worldwide rights to HuMax-CD4 should help us leverage more value from our development work to date. We can build on that to move forward in Europe where we already have an orphan drug designation," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous